icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Phase 1a Safety and Pharmacokinetics (PK) of ABI-H0731,
a Novel Core Protein Allosteric Modifier (CpAM)

 
 
    poster pdf attached
 
Download the PDF here
 
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
 
Edward Gane1,2, Christian Schwabe2, KayshapPatel3, Patrick Smith3, Sandy Liaw4, Eric Ruby4, Kelvin Chan4, Leping Li4, Richard Colonno4and Uri Lopatin4 1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Clinical Trial Unit, Auckland Clinical Studies, Auckland, New Zealand; 3Certara Inc, Princeton, NJ, USA; 4Assembly Biosciences, Inc., San Francisco, CA USA

1108171

1108172

1108173

1108174